As of February 27, 2023, around 77.5 percent of the population in Japan received the second dose of coronavirus disease (COVID-19) vaccination. At the same time, approximately 68.4 percent of the population had a booster shot.

The distribution of COVID-19 vaccination in Japan has begun on February 17, 2021, mainly for health professionals. On April 12, 2021, the government started the vaccine administration for citizens aged 65 and older.

As of February 2023, about 95.8 percent of citizens aged 90 to 99 years in Japan received the third dose of coronavirus disease (COVID-19) vaccinations. The overall share of around 68.4 percent of inhabitants in Japan was vaccinated with the third dose as of the same day.

As of March 16, 2022, close to 79 percent of inhabitants in Akita Prefecture received the second dose of coronavirus disease (COVID-19) vaccination, the highest vaccination rate among all 47 prefectures in Japan. In terms of the booster shot, Yamaguchi Prefecture recorded at around 40.6 percent.

The distribution of COVID-19 vaccination in Japan has begun on February 17, 2021, mainly for health professionals. On April 12, 2021, the government started the vaccine administration for citizens aged 65 and older.

This study evaluated pneumococcal vaccination status using evaluable data collected from 445 of 1,313 managing directors of elderly care facilities in Japan through an online survey (September 5, 2022-November 25, 2022; UMIN000048747); comparisons were made with the influenza (2021–2022 vaccination only) and coronavirus disease 2019 (COVID-19) vaccination status. Among facilities who kept pneumococcal vaccination records (n = 42), the mean pneumococcal vaccination rate was 31.1%, with the rate being higher for the influenza (93.1%; n = 234) and COVID-19 (94.3%; n = 285) vaccines. Overall, excluding facilities that answered that the corresponding vaccine status at their sites was unknown, the percentage of facilities with high vaccination rates (80% to 100%) was substantially higher for the influenza (80.5%; 351/436) and COVID-19 (89.6%; 396/442) vaccines than for the pneumococcal vaccine (6.5%; 24/370). Multivariable analysis showed that major factors associated with a high pneumococcal vaccination rate (≥15%) were “managing director’s willingness to recommend” and “pneumococcal vaccination request from the residents.” The most common reason for their willingness to recommend the pneumococcal vaccine was that it is an effective disease prevention strategy (83.3%; 65/78) and for their unwillingness to recommend the pneumococcal vaccine was the inability to understand the effectiveness of the vaccine (43.6%; 17/39). In conclusion, there is a need to improve pneumococcal vaccination rates in elderly care facilities in Japan. Strategies such as increasing awareness and encouraging pneumococcal vaccine recommendation among managing directors, especially for residents not eligible for the national subsidy program, and providing regular training on the pneumococcal vaccine for staff and residents are required. Pneumococcal vaccination rates and factors associated with the vaccination of elderly care facility residents are important for policymakers and academia when considering the development and implementation of vaccination programs and guidelines for the management of residents in these facilities. This study evaluated how many elderly people living in care facilities in Japan got pneumococcal vaccine, comparing it with their rates of getting influenza (2021–2022 vaccination only) and COVID-19 vaccines. The information was collected from managing directors of these facilities through an online survey (September 5, 2022-November 25, 2022). Of the 1,313 managing directors contacted, 445 responded. Among the 42 facilities that had recorded pneumococcal vaccination history of their residents, the average vaccination rate was 31.1%, which was much lower than the rates for influenza (93.1%) and COVID-19 (94.3%) vaccines. Only a small percentage of facilities (6.5%) had high (80% to 100%) pneumococcal vaccination rates, while most had high rates for influenza (80.5%) and COVID-19 vaccines (89.6%). Managing directors recommending the pneumococcal vaccine and residents requesting it were major factors in higher vaccination rates. Most managing directors who recommended pneumococcal vaccine believed it was effective, while those who did not recommend often did not understand its effectiveness. In conclusion, there is a need to increase pneumococcal vaccination rates in elderly care facilities in Japan. Strategies such as raising awareness among managing directors, encouraging them to recommend the vaccine (especially for residents not covered by national subsidy programs), and providing regular training on the vaccine to staff and residents are required.

As of June 30, 2023, Japan has administered around 310 doses of COVID-19 vaccine per 100 people, the highest in the Asia-Pacific region. In comparison, Papua New Guinea has administered only approximately 7.27 COVID-19 vaccine doses per 100 people.

IntroductionAddresing vaccine hesitancy is considered an important goal in management of the COVID-19 pandemic. We sought to understand what factors influenced people, especially those initially hesitant, to receive two or more vaccine doses within a year of the vaccine’s release.MethodsWe conducted longitudinal Web-based observational studies of 3,870 individuals. The surveys were conducted at four different time points: January 2021, June 2021, September 2021, and December 2021. In the baseline survey (January 2021), we assessed vaccination intention (i.e., “strongly agree” or “agree” [acceptance], “neutral” [not sure], and “disagree” or “strongly disagree” [hesitance]), and assumptions about coronavirus disease (COVID-19), COVID-19 vaccine, COVID-19-related health preventive behavior, and COVID-19 vaccine reliability. In subsequent surveys (December 2021), we assessed vaccination completion (i.e., ≥2 vaccinations). To investigate the relationship between predictors of COVID-19 vaccination completion, a multivariable logistic regression model was applied. Adjusted odds ratios (AORs) and 95% confidence intervals (CIs) were calculated while adjusting for gender, age, marital status, presence of children, household income category, and presence of diseases under treatment. In a stratified analysis, predictors were determined based on vaccination intention.ResultsApproximately 96, 87, and 72% of those who demonstrated acceptance, were not sure, or hesitated had been vaccinated after 1 year, respectively. Overall, significant factors associated with COVID-19 vaccine compliance included the influence of others close to the index participant (social norms) (AOR, 1.80; 95% CI, 1.56–2.08; p < 0.001), vaccine confidence (AOR, 1.39; 95% CI, 1.18–1.64; p < 0.001) and structural constraints (no time, inconvenient location of medical institutions, and other related factors) (AOR, 0.80; 95% CI, 0.70–0.91; p = 0.001). In the group of individuals classified as hesitant, significant factors associated with COVID-19 vaccine compliance included social norms (AOR, 2.43; 95% CI, 1.83–3.22; p < 0.001), confidence (AOR, 1.44; 95% CI, 1.10–1.88; p = 0.008), and knowledge (AOR, 0.69; 95% CI, 0.53–0.88; p = 0.003).DiscussionWe found that dissemination of accurate information about vaccines and a reduction in structural barriers to the extent possible enhanced vaccination rates. Once the need for vaccination becomes widespread, it becomes a social norm, and further improvements in these rates can then be anticipated. Our findings may help enhance vaccine uptake in the future.

While vaccines are pivotal in combating COVID-19, concerns about side effects and complex procedures have hindered complete vaccination. Prior studies suggest that individuals defaulted to opt-out exhibit higher COVID-19 vaccination rates compared to those in opt-in systems. However, these studies were conducted in countries with a tolerant attitude towards vaccination and default changes, targeting specific age groups, and did not address potential deterrents like the increase in cancellation rates on the day, discomfort towards changing defaults, or the possibility of the opt-out effect being a one-time occurrence. Under the hypothesis that the default nature of the COVID-19 vaccination system influences attitudes towards vaccination even in countries conservative about vaccination and default changes like in Japan, we aimed to examine the differences in the first and second dose vaccination rates, cancellation rates, and the number of complaints between the opt-in and opt-out systems for COVID-19 vaccination. An email survey was conducted in 10 cities in A Prefecture, Japan. The results showed not only higher COVID-19 vaccination rates across all comparable age groups in the opt-out group but also a notably smaller decrease in the second-dose vaccination rate compared to the opt-in group, all achieved without any complaints about the system’s introduction. Consequently, it can be inferred that the potential inhibiting factors were largely overcome. Despite some limitations, such as regional specificity, the study suggests that opt-out systems might increase COVID-19 vaccination coverage without leading to significant cancellations or complaints, presenting a promising strategy to facilitate vaccination efforts.

As of March 16, 2022, there was a total of approximately 5.9 million confirmed cases of coronavirus disease (COVID-19) in Japan, with around 529 thousand people needing inpatient treatment.

Development of cases in Japan Generally, the increase of new COVID-19 cases recorded from January to March 2020 in Japan followed a slower trajectory as compared to, for example, China, Europe, or the United States of America. The first reported case of COVID-19 in Japan was confirmed on January 16, 2020, when a man that had returned from Wuhan city, China, was tested positive. The first transmission within Japan was recorded on January 28. The number of new cases then increased tenfold in February. April saw a further acceleration of the infection rate. Consequently, the Japanese government declared a nationwide state of emergency that month. The government announced a state of emergency for the second time in January 2021, the third time in April 2021, and the forth time in the July 2021.

Vaccine rollout The Japanese government started the distribution of COVID-19 vaccination in February 2021, mainly for medical professionals. The administration of vaccination for general citizens commenced in April for senior citizens. The vaccine rate of the population was just over 74.7 percent for second doses as of March 2022.

For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated facts and figure page. 

According to a survey conducted in January 2021, approximately ** percent of surveyed Japanese planned to get a vaccination against the coronavirus (COVID-19). Another around **** percent stated that they decided to get a flu shot after the outbreak of COVID-19. About ** percent of respondents did not plan on getting the COVID-19 vaccine.

BackgroundAccording to a recent paper by Gelfand et al., COVID-19 infection and case mortality rates are closely connected to the strength of social norms: “Tighter” cultures that abide by strict social norms are more successful in combating the pandemic than “looser” cultures that are more permissive. However, countries with similar levels of cultural tightness exhibit big differences in mortality rates. We are investigating potential explanations for this fact. Using data from Germany and Japan—two “tight” countries with very different infection and mortality rates—we examined how differences in socio-demographic and other determinants explain differences in individual preventive attitudes and behaviors.MethodsWe compared preventive attitudes and behaviors in 2020 based on real-time representative survey data and used logit regression models to study how individual attitudes and behaviors are shaped by four sets of covariates: individual socio-demographics, health, personality, and regional-level controls. Employing Blinder-Oaxaca regression techniques, we quantified the extent to which differences in averages of the covariates between Japan and Germany explain the differences in the observed preventive attitudes and behaviors.ResultsIn Germany and Japan, similar proportions of the population supported mandatory vaccination, avoided travel, and avoided people with symptoms of a cold. In Germany, however, a significantly higher proportion washed their hands frequently and avoided crowds, physical contact, public transport, peak-hour shopping, and contact with the elderly. In Japan, a significantly higher proportion were willing to be vaccinated. We also show that attitudes and behaviors varied significantly more with covariates in Germany than in Japan. Differences in averages of the covariates contribute little to explaining the observed differences in preventive attitudes and behaviors between the two countries.ConclusionConsistent with tightness-looseness theory, the populations of Japan and Germany responded similarly to the pandemic. The observed differences in infection and fatality rates therefore cannot be explained by differences in behavior. The major difference in attitudes is the willingness to be vaccinated, which was much higher in Japan. Furthermore, the Japanese population behaved more uniformly across social groups than the German population. This difference in the degree of homogeneity has important implications for the effectiveness of policy measures during the pandemic.

As of March 20, 2023, around 391 doses of COVID-19 vaccines per 100 people in Cuba had been administered, one of the highest COVID-19 vaccine dose rates of any country worldwide. This statistic shows the rate of COVID-19 vaccine doses administered worldwide as of March 20, 2023, by country or territory.

This study examines people’s habituation to COVID-19-related information over almost three years. Using publicly available data from 47 Japanese prefectures, I analyse how human mobility responded to COVID-19-related information, such as the number of COVID-19-infected cases, the declaration of a state of emergency (DSE), and several doses of vaccine using an interactive effects model, which is a type of panel data regression. The results show that Japanese citizens were generally fearful and cautious during the first wave of the unknown infection. As such, a 1% week-on-week increase in the number of infected cases results in a decrease in human mobility by 1.09-percentage-point (pp) week-on-week. However, they gradually became habituated to similar infection information during the subsequent waves, which is reflected in 0.71 pp and 0.29 pp decreases in human mobility in the second and third waves. Nevertheless, the level of habituation decreased in response to the different types of the infection, such as new variants in the fourth wave, with 0.50 pp decrease. By contrast, regarding the DSE, it is more plausible to consider that human mobility responds to varying requests rather than habituate them. Whereas a rapid vaccination program could alleviate people’s concerns. I also find spatial spillovers of infection information on human mobility using a spatial weight matrix included in the regression model. However, there is no evidence of DSE or vaccination spatial spillovers, likely because both are valid only in one’s own prefecture. The implementation of flexible human mobility control policies by closely monitoring human mobility can prevent excessive or insufficient mobility control requests. Such a flexible policy can efficiently suppress infection spread and prevent economic activity reduction more than necessary. These implications are useful for evidence-based policymaking during future pandemics.

IntroductionHealthcare students are more likely to become infected than other university students as they may encounter patients with COVID-19 during clinical training. Vaccination uptake is essential to prevent infection. This study explored factors related to COVID-19 vaccination uptake among healthcare students.MethodsThis cross-sectional study conducted online surveys of undergraduate and graduate nursing and healthcare graduate students from four medical universities in the Tokyo Metropolitan Area of Japan. Data were collected from June to August 2022, when the fourth vaccination program was initiated.ResultsData from 1,169 students were analyzed (response rate = 37.3%). The mean age was 25.1 ± 7.6 years, and most were female (82.3%). Academic majors included nursing (68.0%), medicine (16.3%), dentistry (9.3%), and others (6.4%). Thirty students (2.6%) were not vaccinated, one student (0.1%) had received one vaccination, 997 (85.3%) had received three, and 27 (2.3%) had received four. The major reason for not being vaccinated was insufficient confirmation of its safety (n = 25). Students who had received at least one vaccination (n = 1,139), 965 (84.7%) reported experiencing adverse side effects, the most frequent being pain at the injection site (76.2%), followed by fever (68.3%). In the logistic regression, a greater number of vaccinations (3–4 times) was associated with older age (odds ratio, OR = 1.53), working (OR = 1.67), and more frequent infection-preventive behaviors (OR = 1.05). Significantly fewer students were vaccinated at University B than at University A (OR = 0.46). Additionally, those majoring in subjects other than nursing (OR = 0.28), and students from non-Asian countries (OR = 0.30) were less likely to be vaccinated.DiscussionIt is necessary to pay attention to and encourage the vaccination of students who engage in low levels of preventive behavior, students who are young, international, or unemployed, and those in non-healthcare professional majors.

Snapshot img

Travel Vaccines Market Size 2025-2029

The travel vaccines market size is forecast to increase by USD 7.05 billion, at a CAGR of 10.7% between 2024 and 2029.

Major Market Trends & Insights

North America dominated the market and accounted for a 46% growth during the forecast period.
By the Disease Type - Influenza segment was valued at USD 3.44 billion in 2023
By the End-user - Adult vaccines segment accounted for the largest market revenue share in 2023

Market Size & Forecast

Market Opportunities: USD 112.15 billion
Market Future Opportunities: USD 7.05 billion 
CAGR : 10.7%
North America: Largest market in 2023

Market Summary

The market is a significant sector within the healthcare industry, demonstrating continuous growth and evolution. According to various market research, the demand for travel vaccines is on the rise, with an estimated 250 million international travelers in 2020. This number is projected to reach 380 million by 2027, representing a substantial increase. Travelers' changing demographics and increased global connectivity contribute to this market expansion. For instance, an aging population and the rise of adventure tourism are key factors driving the need for diverse travel vaccines. Moreover, the market is witnessing the emergence of new vaccine types, such as combination vaccines, which offer enhanced protection against multiple diseases.
The market's dynamism is further fueled by advancements in technology, enabling the development of more effective and convenient vaccine delivery methods. For example, the use of microneedle patches and oral vaccines is gaining popularity due to their ease of administration and improved patient compliance. Despite these positive trends, challenges persist, including the lack of comprehensive vaccine coverage in some health plans and the ongoing impact of the COVID-19 pandemic on travel vaccination services. Nonetheless, the market's potential for growth remains strong, with opportunities for collaboration between stakeholders, including pharmaceutical companies, travel agencies, and healthcare providers.

What will be the Size of the Travel Vaccines Market during the forecast period?

Explore market size, adoption trends, and growth potential for travel vaccines market Request Free Sample

Travel vaccines represent a significant segment within the healthcare industry, with current market participation exceeding 20%. This figure underscores the importance of travel vaccines in safeguarding the health of globally mobile populations. Looking ahead, market expansion is anticipated to surpass 15% annually, driven by increasing awareness of disease prevention and the continuous development of innovative vaccine formulations. The market demonstrates a dynamic equilibrium between vaccine efficacy and patient compliance. For instance, in 2020, vaccine recommendations for hepatitis A and typhoid fever reached 90% and 70%, respectively, reflecting high levels of adherence. In contrast, compliance for yellow fever and rabies vaccines stood at 60% and 40%, respectively.
This disparity underscores the importance of effective vaccine education and public health initiatives to boost compliance rates and ultimately improve disease prevention. Moreover, advancements in vaccine manufacturing, cold chain management, and adjuvant systems have led to increased vaccine availability and efficacy. For example, cellular immunity responses to certain vaccines have shown promising results, leading to enhanced protection against various diseases. These advancements not only contribute to the market's growth but also improve overall traveler health and safety.

How is this Travel Vaccines Industry segmented?

The travel vaccines industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Disease Type

  Influenza
  Diptheria
  Hepatitis
  Typhoid and others


End-user

  Adult vaccines
  Pediatric vaccines


Type

  Outbound
  Inbound


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan


  South America

    Brazil


  Rest of World (ROW)

By Disease Type Insights

The influenza segment is estimated to witness significant growth during the forecast period.

The market, specifically for influenza, is experiencing substantial expansion due to several factors. The resurgence of leisure and corporate travel to pre-pandemic levels and the increasing health awareness among travelers are primary drivers. Influenza vaccines are easily accessible, as they are widely available at pharmacies, healthcare facilities, and workplaces, making administration convenient for travelers. Moreover, disease surveilla

Unlike many other countries, the COVID-19 vaccination rate among the elderly population in China is lower than that among other age groups. As of **************, only around half of the Chinese residents aged 80 years and older were fully vaccinated against COVID-19, while less than ** percent had received a booster shot. In comparison, as of **************, ** percent of Japanese elderlies between 80 and 89 years are fully vaccinated against COVID-19.

On March 10, 2023, the Johns Hopkins Coronavirus Resource Center ceased its collecting and reporting of global COVID-19 data. For updated cases, deaths, and vaccine data please visit the following sources: World Health Organization (WHO)For more information, visit the Johns Hopkins Coronavirus Resource Center.-- Esri COVID-19 Trend Report for 3-9-2023 --0 Countries have Emergent trend with more than 10 days of cases: (name : # of active cases) 41 Countries have Spreading trend with over 21 days in new cases curve tail: (name : # of active cases)Monaco : 13, Andorra : 25, Marshall Islands : 52, Kyrgyzstan : 79, Cuba : 82, Saint Lucia : 127, Cote d'Ivoire : 148, Albania : 155, Bosnia and Herzegovina : 172, Iceland : 196, Mali : 198, Suriname : 246, Botswana : 247, Barbados : 274, Dominican Republic : 304, Malta : 306, Venezuela : 334, Micronesia : 346, Uzbekistan : 356, Afghanistan : 371, Jamaica : 390, Latvia : 402, Mozambique : 406, Kosovo : 412, Azerbaijan : 427, Tunisia : 528, Armenia : 594, Kuwait : 716, Thailand : 746, Norway : 768, Croatia : 847, Honduras : 1002, Zimbabwe : 1067, Saudi Arabia : 1098, Bulgaria : 1148, Zambia : 1166, Panama : 1300, Uruguay : 1483, Kazakhstan : 1671, Paraguay : 2080, Ecuador : 53320 Countries may have Spreading trend with under 21 days in new cases curve tail: (name : # of active cases)61 Countries have Epidemic trend with over 21 days in new cases curve tail: (name : # of active cases)Liechtenstein : 48, San Marino : 111, Mauritius : 742, Estonia : 761, Trinidad and Tobago : 1296, Montenegro : 1486, Luxembourg : 1540, Qatar : 1541, Philippines : 1915, Ireland : 1946, Brunei : 2010, United Arab Emirates : 2013, Denmark : 2111, Sweden : 2149, Finland : 2154, Hungary : 2169, Lebanon : 2208, Bolivia : 2838, Colombia : 3250, Switzerland : 3321, Peru : 3328, Slovakia : 3556, Malaysia : 3608, Indonesia : 3793, Portugal : 4049, Cyprus : 4279, Argentina : 5050, Iran : 5135, Lithuania : 5323, Guatemala : 5516, Slovenia : 5689, South Africa : 6604, Georgia : 7938, Moldova : 8082, Israel : 8746, Bahrain : 8932, Netherlands : 9710, Romania : 12375, Costa Rica : 12625, Singapore : 13816, Serbia : 14093, Czechia : 14897, Spain : 17399, Ukraine : 19568, Canada : 24913, New Zealand : 25136, Belgium : 30599, Poland : 38894, Chile : 41055, Australia : 50192, Mexico : 65453, United Kingdom : 65697, France : 68318, Italy : 70391, Austria : 90483, Brazil : 134279, Korea - South : 209145, Russia : 214935, Germany : 257248, Japan : 361884, US : 6440500 Countries may have Epidemic trend with under 21 days in new cases curve tail: (name : # of active cases) 54 Countries have Controlled trend: (name : # of active cases)Palau : 3, Saint Kitts and Nevis : 4, Guinea-Bissau : 7, Cabo Verde : 8, Mongolia : 8, Benin : 9, Maldives : 10, Comoros : 10, Gambia : 12, Bhutan : 14, Cambodia : 14, Syria : 14, Seychelles : 15, Senegal : 16, Libya : 16, Laos : 17, Sri Lanka : 19, Congo (Brazzaville) : 19, Tonga : 21, Liberia : 24, Chad : 25, Fiji : 26, Nepal : 27, Togo : 30, Nicaragua : 32, Madagascar : 37, Sudan : 38, Papua New Guinea : 38, Belize : 59, Egypt : 60, Algeria : 64, Burma : 65, Ghana : 72, Haiti : 74, Eswatini : 75, Guyana : 79, Rwanda : 83, Uganda : 88, Kenya : 92, Burundi : 94, Angola : 98, Congo (Kinshasa) : 125, Morocco : 125, Bangladesh : 127, Tanzania : 128, Nigeria : 135, Malawi : 148, Ethiopia : 248, Vietnam : 269, Namibia : 422, Cameroon : 462, Pakistan : 660, India : 4290 41 Countries have End Stage trend: (name : # of active cases)Sao Tome and Principe : 1, Saint Vincent and the Grenadines : 2, Somalia : 2, Timor-Leste : 2, Kiribati : 8, Mauritania : 12, Oman : 14, Equatorial Guinea : 20, Guinea : 28, Burkina Faso : 32, North Macedonia : 351, Nauru : 479, Samoa : 554, China : 2897, Taiwan* : 249634 -- SPIKING OF NEW CASE COUNTS --20 countries are currently experiencing spikes in new confirmed cases:Armenia, Barbados, Belgium, Brunei, Chile, Costa Rica, Georgia, India, Indonesia, Ireland, Israel, Kuwait, Luxembourg, Malaysia, Mauritius, Portugal, Sweden, Ukraine, United Kingdom, Uzbekistan 20 countries experienced a spike in new confirmed cases 3 to 5 days ago: Argentina, Bulgaria, Croatia, Czechia, Denmark, Estonia, France, Korea - South, Lithuania, Mozambique, New Zealand, Panama, Poland, Qatar, Romania, Slovakia, Slovenia, Switzerland, Trinidad and Tobago, United Arab Emirates 47 countries experienced a spike in new confirmed cases 5 to 14 days ago: Australia, Austria, Bahrain, Bolivia, Brazil, Canada, Colombia, Congo (Kinshasa), Cyprus, Dominican Republic, Ecuador, Finland, Germany, Guatemala, Honduras, Hungary, Iran, Italy, Jamaica, Japan, Kazakhstan, Lebanon, Malta, Mexico, Micronesia, Moldova, Montenegro, Netherlands, Nigeria, Pakistan, Paraguay, Peru, Philippines, Russia, Saint Lucia, Saudi Arabia, Serbia, Singapore, South Africa, Spain, Suriname, Thailand, Tunisia, US, Uruguay, Zambia, Zimbabwe 194 countries experienced a spike in new confirmed cases over 14 days ago: Afghanistan, Albania, Algeria, Andorra, Angola, Antigua and Barbuda, Argentina, Armenia, Australia, Austria, Azerbaijan, Bahamas, Bahrain, Bangladesh, Barbados, Belarus, Belgium, Belize, Benin, Bhutan, Bolivia, Bosnia and Herzegovina, Botswana, Brazil, Brunei, Bulgaria, Burkina Faso, Burma, Burundi, Cabo Verde, Cambodia, Cameroon, Canada, Central African Republic, Chad, Chile, China, Colombia, Comoros, Congo (Brazzaville), Congo (Kinshasa), Costa Rica, Cote d'Ivoire, Croatia, Cuba, Cyprus, Czechia, Denmark, Djibouti, Dominica, Dominican Republic, Ecuador, Egypt, El Salvador, Equatorial Guinea, Eritrea, Estonia, Eswatini, Ethiopia, Fiji, Finland, France, Gabon, Gambia, Georgia, Germany, Ghana, Greece, Grenada, Guatemala, Guinea, Guinea-Bissau, Guyana, Haiti, Honduras, Hungary, Iceland, India, Indonesia, Iran, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kenya, Kiribati, Korea - South, Kosovo, Kuwait, Kyrgyzstan, Laos, Latvia, Lebanon, Lesotho, Liberia, Libya, Liechtenstein, Lithuania, Luxembourg, Madagascar, Malawi, Malaysia, Maldives, Mali, Malta, Marshall Islands, Mauritania, Mauritius, Mexico, Micronesia, Moldova, Monaco, Mongolia, Montenegro, Morocco, Mozambique, Namibia, Nauru, Nepal, Netherlands, New Zealand, Nicaragua, Niger, Nigeria, North Macedonia, Norway, Oman, Pakistan, Palau, Panama, Papua New Guinea, Paraguay, Peru, Philippines, Poland, Portugal, Qatar, Romania, Russia, Rwanda, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Samoa, San Marino, Sao Tome and Principe, Saudi Arabia, Senegal, Serbia, Seychelles, Sierra Leone, Singapore, Slovakia, Slovenia, Solomon Islands, Somalia, South Africa, South Sudan, Spain, Sri Lanka, Sudan, Suriname, Sweden, Switzerland, Syria, Taiwan*, Tajikistan, Tanzania, Thailand, Timor-Leste, Togo, Tonga, Trinidad and Tobago, Tunisia, Turkey, Tuvalu, US, Uganda, Ukraine, United Arab Emirates, United Kingdom, Uruguay, Uzbekistan, Vanuatu, Venezuela, Vietnam, West Bank and Gaza, Yemen, Zambia, Zimbabwe Strongest spike in past two days was in US at 64,861 new cases.Strongest spike in past five days was in US at 64,861 new cases.Strongest spike in outbreak was 424 days ago in US at 1,354,505 new cases. Global Total Confirmed COVID-19 Case Rate of 8620.91 per 100,000Global Active Confirmed COVID-19 Case Rate of 37.24 per 100,000Global COVID-19 Mortality Rate of 87.69 per 100,000 21 countries with over 200 per 100,000 active cases.5 countries with over 500 per 100,000 active cases.3 countries with over 1,000 per 100,000 active cases.1 country with over 2,000 per 100,000 active cases.Nauru is worst at 4,354.54 per 100,000.

In January 2021, ** percent of respondents in Japan who did not want to take a vaccine for COVID-19 stated that they were worried about the side effects. This statistic illustrates the reasons cited for not getting vaccinated against COVID-19 worldwide as of January 2021.

Based on a comparison of coronavirus deaths in 210 countries relative to their population, Peru had the most losses to COVID-19 up until July 13, 2022. As of the same date, the virus had infected over 557.8 million people worldwide, and the number of deaths had totaled more than 6.3 million. Note, however, that COVID-19 test rates can vary per country. Additionally, big differences show up between countries when combining the number of deaths against confirmed COVID-19 cases. The source seemingly does not differentiate between "the Wuhan strain" (2019-nCOV) of COVID-19, "the Kent mutation" (B.1.1.7) that appeared in the UK in late 2020, the 2021 Delta variant (B.1.617.2) from India or the Omicron variant (B.1.1.529) from South Africa.

The difficulties of death figures

This table aims to provide a complete picture on the topic, but it very much relies on data that has become more difficult to compare. As the coronavirus pandemic developed across the world, countries already used different methods to count fatalities, and they sometimes changed them during the course of the pandemic. On April 16, for example, the Chinese city of Wuhan added a 50 percent increase in their death figures to account for community deaths. These deaths occurred outside of hospitals and went unaccounted for so far. The state of New York did something similar two days before, revising their figures with 3,700 new deaths as they started to include “assumed” coronavirus victims. The United Kingdom started counting deaths in care homes and private households on April 29, adjusting their number with about 5,000 new deaths (which were corrected lowered again by the same amount on August 18). This makes an already difficult comparison even more difficult. Belgium, for example, counts suspected coronavirus deaths in their figures, whereas other countries have not done that (yet). This means two things. First, it could have a big impact on both current as well as future figures. On April 16 already, UK health experts stated that if their numbers were corrected for community deaths like in Wuhan, the UK number would change from 205 to “above 300”. This is exactly what happened two weeks later. Second, it is difficult to pinpoint exactly which countries already have “revised” numbers (like Belgium, Wuhan or New York) and which ones do not. One work-around could be to look at (freely accessible) timelines that track the reported daily increase of deaths in certain countries. Several of these are available on our platform, such as for Belgium, Italy and Sweden. A sudden large increase might be an indicator that the domestic sources changed their methodology.

Where are these numbers coming from?

The numbers shown here were collected by Johns Hopkins University, a source that manually checks the data with domestic health authorities. For the majority of countries, this is from national authorities. In some cases, like China, the United States, Canada or Australia, city reports or other various state authorities were consulted. In this statistic, these separately reported numbers were put together. For more information or other freely accessible content, please visit our dedicated Facts and Figures page.

Physical and mental parameters for characterization of patients with ME/CFS related to long COVID and non-ME/CFS patients.

Among infectious diseases that were recorded in Japan, the highest number of deaths was caused by the coronavirus disease (COVID-19), which amounted to ****** deaths in 2023. The number of deaths from infectious enterogastritis followed with around ***** cases.  Seasonal influenza in Japan  The influenza season in Japan typically begins in November or December and reaches its peak in the first two months of the following year. The number of deaths caused by seasonal flu in Japan has been increasing in recent years. Since 2010, more than ** million influenza vaccine units have been supplied in the country annually. Citizens aged 60 years and over are eligible to receive free periodic influenza vaccines from their municipality. Around ** million elderly have received such a free vaccination yearly. Receding flu infections during COVID-19 During the COVID-19 pandemic, a partial decrease in monthly flu patients was observed in Japan. This development was partially attributed to a phenomenon called viral interference, making people less susceptible to influenza viruses in areas where the coronavirus is predominant. In case of an infection with the novel virus, infected cells secrete so-called interferon proteins, which block other viruses. Nationwide preventive measures such as face masks, home office implementation, and regulations of gastronomy opening hours had also shown a positive influence on reducing infection numbers of diseases like influenza.